Anavex Receives Regulatory Approval to Initiate Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS for Alzheimer’s disease
Institutional Investor Lincoln Park Capital Increases Ownership in Anavex, Pays Over 25% Premium to Market
Anavex Supports Alzheimer’s Foundation of America’s 3rd Annual Concepts in Care Educational Conference
Anavex Selects The Alfred Hospital in Melbourne, Australia as Lead Site for Phase 2a Alzheimer’s Clinical Trial